Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs

Yesterday afternoon, Neuren Pharmaceuticals Ltd (ASX: NEU) shared feedback from recent US FDA meetings on its NNZ-2591 clinical programs. Neuren said it received constructive guidance for its development plans in hypoxic ischemic encephalopathy (HIE) and Pitt Hopkins syndrome (PTHS), with minimal impact on funding or timelines.

What did Neuren Pharmaceuticals report?

• Received written feedback from the US FDA for NNZ-2591 development in both HIE and PTHS.
• FDA generally accepted Neuren’s plans for an IND-opening clinical study in HIE and offered input on study criteria and safety monitoring.
• FDA recommended additional juvenile animal data to support dosing in neonatal HIE studies, with plans to generate this data ahead of next steps.
• For PTHS, FDA supported use of a clinical global impression (CGI) scale as a co-primary endpoint with an observer-reported measure.
• Neuren anticipates providing an update on its Koala Phase 3 Phelan-McDermid syndrome trial soon.

What else do investors need to know?

Neuren described the FDA’s response process as delayed and conducted entirely in writing, rather than face-to-face meetings. However, the company remains confident it has a “clear path forward” for both HIE and PTHS programs.

For HIE, initial clinical studies are targeted to start later in 2026, after extra preclinical data is complete and an IND application is submitted. Meanwhile, Neuren is exploring trial design options for PTHS to suit its rarity and the severity of the condition, flagging a likely need for further FDA engagement before commencing the next study.

What did Neuren Pharmaceuticals management say?

CEO Jon Pilcher said:

We received useful guidance from FDA for our programs in Pitt Hopkins syndrome and HIE and are incorporating the feedback into our plans, although we were disappointed that in both cases the guidance was received as Written Responses Only and was delayed relative to FDA’s goal dates. Overall, we have a clear path forward and remain well positioned to fund the programs, with minimal financial impact from the feedback. We remain committed to advancing NNZ-2591 as a potential treatment option for both the HIE and Pitt Hopkins communities, which have such urgent unmet need. In the meantime, we anticipate being able to provide an update shortly on progress in the ongoing Koala Phase 3 trial in Phelan-McDermid syndrome, our lead program for NNZ-2591.

What’s next for Neuren Pharmaceuticals?

Neuren plans to generate the additional animal study data required by the FDA and then proceed with its IND application for HIE, aiming for clinical trial startup later in 2026. The company also intends to finalise the optimal trial design for a future PTHS study, including consulting the FDA as needed.

Investors can look for upcoming news on Neuren’s Koala Phase 3 trial for Phelan-McDermid syndrome, which is its most advanced NNZ-2591 program. The company says it is well resourced to fund ongoing clinical work.

Neuren Pharmaceuticals share price snapshot

Over the past 12 month, Neuren Pharmaceuticals shares have risen 11%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 7% over the same period.

View Original Announcement

The post Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Neuren Pharmaceuticals shares paused pending announcement
• Amcor earnings: Net sales rocket 68% on Berry deal; guidance reaffirmed
• Abacus Storage King weighs management internalisation: What investors need to know
• Are these 2 ASX healthcare shares a buying opportunity after yesterday’s crash?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.